Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial

被引:129
作者
Oosterheert, Jan Jelrik
Bonten, Marc J. M.
Schneider, Margriet M. E.
Buskens, Erik
Lammers, Jan-Willem J.
Hustinx, Willem M. N.
Kramer, Mark H. H.
Prins, Jan M.
Slee, Peter H. Th. J.
Kaasjager, Karin
Hoepelman, Andy I. M.
机构
[1] Univ Med Ctr, Dept Internal Med & Infect Dis, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[3] Univ Med Ctr, Dept Pulmonol, NL-3508 GA Utrecht, Netherlands
[4] Diakonessen Hosp, Dept Internal Med, Utrecht, Netherlands
[5] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands
[6] Acad Med Ctr, Dept Internal Med, Div Infect Dis & Trop Med & Aids, Amsterdam, Netherlands
[7] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands
[8] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands
来源
BMJ-BRITISH MEDICAL JOURNAL | 2006年 / 333卷 / 7580期
关键词
D O I
10.1136/bmj.38993.560984.BE
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To compare the effectiveness of an early switch to oral antibiotics with the standard 7 day course of intravenous antibiotics in severe community acquired pneumonia. Design Multicentre randomised controlled trial. Setting Five teaching hospitals and 2 university medical centres in the Netherlands. Participants 302 patients in non-intensive care wards with severe community acquired pneumonia. 265 patients fulfilled the stud), requirements. Intervention Three days of treatment with intravenous antibiotics followed, when clinically stable, by oral antibiotics or by 7 days of intravenous antibiotics. Main outcome measures Clinical cure and length of hospital stays Results 302 patients were randomised. (mean age 69.5 (standard deviation 14.0), mean pneumonia severity score 112.7 (26.0)). 37 patients were excluded from analysis because of early dropout before day 3, leaving 265 patients for intention to treat analysis. Mortality at clay 28 was 4% in the intervention group and 6% in the control group (mean difference 2%,95% confidence interval - 3% to 8%). Clinical cure was 83% in the intervention group and 85% in the control group (2%, - 7% to 10%). Duration of intravenous treatment and length of hospital stay were reduced in the intervention group, with mean differences of 3.4 days (3.6 (1.5) v 7.0 (2.0) days; 2.8 to 3.9) and 1.9 days (9.6 (5.0) v 11.5 (4.9) days; 0.6 to 3.2), respectively Conclusions Early switch from intravenous to oral antibiotics in patients with severe community acquired pneumonia is safe and decreases length of hospital stay by 2 days.
引用
收藏
页码:1193 / 1195
页数:5
相关论文
共 21 条
[1]   Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia:: A randomized controlled trial [J].
Castro-Guardiola, A ;
Viejo-Rodríguez, AL ;
Soler-Simon, S ;
Armengou-Arxé, A ;
Bisbe-Company, V ;
Peñarroja-Matutano, G ;
Bisbe-Company, J ;
García-Bragado, F .
AMERICAN JOURNAL OF MEDICINE, 2001, 111 (05) :367-374
[2]   EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF RESPIRATORY-TRACT INFECTIONS [J].
CHOW, AW ;
HALL, CB ;
KLEIN, JO ;
KAMMER, RB ;
MEYER, RD ;
REMINGTON, JS .
CLINICAL INFECTIOUS DISEASES, 1992, 15 :S62-S88
[3]   A prediction rule to identify low-risk patients with community-acquired pneumonia [J].
Fine, MJ ;
Auble, TE ;
Yealy, DM ;
Hanusa, BH ;
Weissfeld, LA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Kapoor, WN .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) :243-250
[4]   Community-acquired pneumonia: The annual cost to the national health service in the UK [J].
Guest, JF ;
Morris, A .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) :1530-1534
[5]   Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia [J].
Halm, EA ;
Fine, MJ ;
Kapoor, WN ;
Singer, DE ;
Marrie, TJ ;
Siu, AL .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (11) :1278-1284
[6]   SEROLOGICAL DIAGNOSIS OF MYCOPLASMA-PNEUMONIAE INFECTIONS - A CRITICAL-REVIEW OF CURRENT PROCEDURES [J].
JACOBS, E .
CLINICAL INFECTIOUS DISEASES, 1993, 17 :S79-S82
[7]   A controlled trial of a critical pathway for treatment of community-acquired pneumonia [J].
Marrie, TJ ;
Lau, CY ;
Wheeler, SL ;
Wong, CJ ;
Vandervoort, MK ;
Feagan, BG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (06) :749-755
[8]  
Marston Barbara J., 1997, Archives of Internal Medicine, V157, P1709, DOI 10.1001/archinte.157.15.1709
[9]   Guidelines for the management of adults with community-acquired pneumonia - Diagnosis, assessment of severity, antimicrobial therapy, and prevention [J].
Niederman, MS ;
Mandell, LA ;
Anzueto, A ;
Bass, JB ;
Broughton, WA ;
Campbell, GD ;
Dean, N ;
File, T ;
Fine, MJ ;
Gross, PA ;
Martinez, F ;
Marrie, TJ ;
Plouffe, JF ;
Ramirez, J ;
Sarosi, GA ;
Torres, A ;
Wilson, R ;
Yu, VL .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (07) :1730-1754
[10]   Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis [J].
Omidvari, K ;
de Boisblanc, BP ;
Karam, G ;
Nelson, S ;
Haponik, E ;
Summer, W .
RESPIRATORY MEDICINE, 1998, 92 (08) :1032-1039